

EMA/352636/2022

European Medicines Agency decision

P/0198/2022

of 2 June 2022

on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP03-16-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0198/2022

of 2 June 2022

on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMA-001741-PIP03-16-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0046/2018 issued on 16 February 2018 and the decision P/0069/2019 issued on 22 March 2019,

Having regard to the application submitted by AbbVie Ltd on 10 March 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 May 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for upadacitinib (Rinvoq), age-appropriate oral liquid dosage form, age-appropriate oral solid dosage form, prolonged-release tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0288/2015 issued on 27 November 2015, including subsequent modifications thereof and the decision P/0394/2018 issued on 7 December 2018, including subsequent modifications thereof.

Article 3

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, SL6 4UB - Maidenhead, United Kingdom.

EMA/PDCO/180114/2022
Amsterdam, 20 May 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001741-PIP03-16-M02

Scope of the application

Active substance(s):

Upadacitinib

Invented name:

Rinvoq

Condition(s):

Treatment of Crohn's disease

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Age-appropriate oral liquid dosage form

Age-appropriate oral solid dosage form

Prolonged-release tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted to the European Medicines Agency on 10 March 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0046/2018 issued on 16 February 2018 and the decision P/0069/2019 issued on 22 March 2019.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 25 April 2022.

Scope of the modification

Administrative modification to link this PIP with PIP decisions covering all authorised indications of upadacitinib (PIP P/0288/2015 for chronic idiopathic arthritis and PIP P/0394/2018 for atopic dermatitis, including subsequent modifications thereof).

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.
2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Crohn's disease

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- prolonged-release tablet, age-appropriate oral pharmaceutical form, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of Crohn's disease (CD)

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with moderately to severely active Crohn's disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Prolonged-release tablet

Age-appropriate oral pharmaceutical form

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Age-appropriate oral solid dosage form (dispersible tablet or multi-particulate granules) or age-appropriate oral liquid dosage form.
Non-clinical studies	Study 2 Dose range-finding juvenile toxicity study. Study 3 Definitive juvenile toxicity study to evaluate toxicity and impact of upadacitinib on neonatal/juvenile development.

Clinical studies	Study 4 Double-blind safety, efficacy, and pharmacokinetic study with an open label induction phase of upadacitinib in children from 2 to less than 18 years with moderately to severely active Crohn's disease, who have had an inadequate response or been intolerant to corticosteroids, immunosuppressants, and/or biologic therapy, or have medical contraindications to such therapies. (M14-671).
Extrapolation, modelling and simulation studies	Study 5 Population PK modelling and simulation study to determine the dose of upadacitinib in children from 2 to less than 18 years of age with Crohn's disease.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Chronic Idiopathic Arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

Authorised indication(s):

Rheumatoid arthritis

- RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

- RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Ankylosing spondylitis

- RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

2. Treatment of atopic dermatitis

Authorised indication(s):

RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Authorised pharmaceutical form(s):

Prolonged-release tablet

Authorised route(s) of administration:

Oral use